Cover Image
市場調查報告書

主要已開發國家的卵巢癌市場:改善無惡化存活期再加上以標的療法為焦點,臨床實驗最後階段的開發中產品

Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies

出版商 GBI Research 商品編碼 302277
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
主要已開發國家的卵巢癌市場:改善無惡化存活期再加上以標的療法為焦點,臨床實驗最後階段的開發中產品 Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies
出版日期: 2014年05月12日 內容資訊: 英文
簡介

目前大部分卵巢癌治療藥為含鉑類藥物,可使70%的患者達到寬解。但之後再發的病例也不在少數,此外也極需對鉑類化合物無效的患者之治療方法。於是以患者為對象的平台開發產品便在開發中,目前已快達到實驗最終階段。全球卵巢癌市場預測今後將以年複合成長率(CAGR)3.4%的速度成長,到2020年市場規模將達19億美元。

本報告提供全球主要已開發國家(美國·英國·法國·德國·義大利·西班牙·日本)的卵巢癌治療藥市場相關分析,提供疾病概要和目前主要治療方法,現在已上市·臨床實驗中的主要治療藥概要與臨床實驗的進展,全球及各國的市場趨勢預測(今後7年份),主要的推動及阻礙市場要素,市場最新趨勢(資本交易·共同開發等),今後的市場方向性等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

  • 病理
    • 卵巢癌:各種疾病的一群
    • 卵巢癌:異種遺傳基因性高,多重突然變異的一種,受影響的信號途徑數也多
  • 症狀與診斷
  • 風險要素
    • 年齡
    • 繼承突然變異遺傳基因
    • 一生排卵數的增加
    • 體重
    • 以前的健康狀態
  • 治療流程
    • 外科手術
    • 第一選擇的化療
    • 維持療法
  • 疾病的復發

第3章 已上市產品

  • Carboplatin
  • Paclitaxel
  • 健擇
  • topotekan
  • 聚乙二醇化微脂體阿霉素
  • Yondelis
  • Avastin

第4章 產品平台

  • 開發平台概要:PHASE別·各投藥法
  • 開發平台概要:分子類別·各行動機制·分子標的別
    • 開發平台的分子標的
  • 臨床實驗
    • 臨床實驗的持續期間
    • 臨床實驗的規模
    • 失敗率
    • 資訊公開

第5章 臨床實驗的最後階段醫藥品

  • 產品簡介
    • Niraparib
    • Olaparib
    • Abagovomab
    • Vargatef
    • Trebananib
    • Farletuzumab
    • Vynfinit
    • Telcyta
    • Karenitecin
  • 議論

第6章 市場預測

  • 全球市場
    • 概況
    • 主要國家的治療模式和收益額
  • 北美市場
    • 治療方法的利用模式
    • 年度治療費用
    • 市場收益
  • 歐洲主要5個國家的市場
  • 日本市場

第7章 市場促進·阻礙因素

  • 推動市場要素
    • 目前開發中的多數候補藥
    • 臨床方面的高度未滿足需求
    • 開發孤兒藥的輔助金
    • 變更臨床實驗設計的可能性
  • 市場阻礙因素
    • 發病率低
    • 細胞株的不足
    • 疾病的異種混合度高
    • 新藥的成本過高

第8章 資本交易趨勢

  • 授權合約(全部11件)
  • 共同開發契約(全3件)

第9章 附錄

圖表一覽

目錄
Product Code: GBIHC329MR

GBI Research, has released the pharma report - "Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies". The current Ovarian cancer therapeutics market is dominated by the use of generics - predominately carboplatin and paclitaxel, which are used in combination for the treatment of platinum-sensitive disease (both first-line and recurrent). Initial treatment with platinum-based therapy is usually effective, with approximately 70% of patients entering remission. However, even with extended progression free-survival of 24 months, almost all patients relapse, and after successive periods of remission and relapse either die or progress to platinum-resistant disease, for which the prognosis is poor. There is a clear gap in the market for maintenance therapies to extend the initial high rates of remission, and hopefully stimulate long-term remission in patients. As well as a gap for more effective treatment options in platinum-resistant or refractory patients.

The current developmental pipeline addresses these gaps in the market, with five of the 10 late stage pipeline molecules indicated as maintenance therapies, and three of the 10 indicated in platinum-resistant disease. However, efficacy with these late stage drugs has been poor, at best demonstrating minimal improvements in PFS. In the EU, both Avastin and Yondelis have been approved on the basis of improvements in PFS alone. It is expected therefore, that those pipeline drugs that have demonstrated the most significant improvements in PFS - olaparib, Vynfinit and trebananib, will be approved in this territory. However even on approval, the lack of an overwhelming improvement in clinical benefit with these drugs, and their expected high cost will limit their sales. In the US, the improvement in PFS observed with Yondelis and Avastin, in the absence of any other clinical benefit with either drug, resulted in neither drug being approved by the FDA. In line with these rejections, the improvements in PFS alone, observed with the current late stage pipeline drugs, is expected to result in the failure of any drug to be approved in the US within the forecast period.

As a result the global market is expected not be driven by new drug approvals, but primarily inflation, and the increase in the prevalence of pancreatic cancer. Global market revenues are forecast to rise at a limited CAGR of 3.4% to $1.9billion in 2020.

Despite the poor results obtained with late stage pipeline drugs there is evidence of continued interest in the ovarian cancer market, with a high number of drug candidates in the current developmental pipeline, particularly at the Preclinical Phase. There is a wide range of novel molecular targets distributed amongst these drug candidates, including growth factors, serine/threonine protein kinases and tumor associated antigens. This suggests a continued interest in introducing more targeted therapies into the treatment of OC, the use of which in this indication lags significantly behind that in other indications in oncology.

Scope

The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts across indications for pancreatic cancer. The report covers and includes -

  • A brief introduction to ovarian cancer, including the disease's pathogenesis, risk factors and diagnosis.
  • In-depth analysis of the drug combinations used in the treatment of ovarian cancer, including analyses of their safety, efficacy, and place in the disease treatment algorithm. This includes a heat map comparing the drug combination in terms of safety and efficacy.
  • Comprehensive review of the pipeline for ovarian cancer therapies, including individual analysis of a number of late-stage pipeline drugs that have the potential to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets, as well as administration routes.
  • Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action.
  • Multi-scenario forecast data of the market to 2020, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets including the US, Canada, Japan, Germany, the UK, France, Italy and Spain.
  • Discussion of the drivers and barriers for market growth.
  • An in-depth analysis of licensing and co-development deals involving drugs indicated in ovarian cancer, including an in-depth outline of the key deals.

Reasons to buy

  • The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to -
  • Understanding the efficacy and safety of the current monotherapies and drug combinations used in the treatment of ovarian cancer, with an in-depth analysis of the disease treatment algorithm.
  • Understand the key signalling pathways and molecular targets currently inder investigation in drug development for ovarian cancer
  • Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent.
  • Observe the trends in clinical trial duration and size amongst clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for pancreatic cancer therapeutics.
  • Assess the potential clinical and commercial impact of current late-stage pipeline molecules in the ovarian cancer therapeutics market.

Abstract

Population Growth and Inflation to Drive Market

GBI Research has identified and analyzed 10 promising late-stage pipeline drugs (see section 5). However, of these 10, only Telik's Telcyta has been shown to improve median patient Overall Survival (OS); however, questions raised over the validity of the data mean that the drug is not expected to be approved within the forecast period of 2013-2020. Further Phase III trials of the drug are required, for which Telcyta is currently seeking corporate partners. Most of the late-stage drugs provide no clinical benefit to patients, with the best responses being mild to moderate improvements in Progression-Free Survival (PFS) in comparison with standard-of care treatment. In the projected scenario, those drugs that have been shown to provide an improvement in PFS will be approved in the EU, Canada and Japan. These are Vynfinit, olaparib and Trebananib. This is in line with the most recent drug approvals in these markets: Avastin and Yondelis, which were approved on the basis of improved PFS. However, the expected high cost of these drugs and their minimal clinical benefit, are expected to create a negative opinion of them among healthcare professionals and regulatory bodies in these three geographies, limiting their prescription volumes.

In the US, the improvements in PFS observed with Yondelis and Avastin were not sufficient for either drug to be granted approval in the US. However, despite its refusal, Avastin is approved for other indications within oncology, with evidence that the drug is prescribed off-label for the treatment of Ovarian Cancer (OC) in the US, contributing significantly to the current market (Burger, 2007). The inflation of Avastin, which costs up to $100,000 for a course of treatment, is expected to be a major contributor to market growth in the US and globally. Given the similar lack of OS benefit with current late-stage pipeline drugs, it is unlikely the aforementioned late-stage pipeline drugs will be approved in the US within the forecast period.

Despite the lack of new approvals in this territory the growth of the global market is expected to be driven primarily by growth in the US market. As discussed, no new drugs are expected to be approved in this territory, in which there is a small increase in the prevalence population. Growth is expected to instead be driven by inflation on the cost of therapy, which currently averages $30,000. Inflationary pressure on Avastin, in particular is expected to drive growth. This high inflation rate, not observed across other territories, will result in the North American market becoming increasingly dominant in the global market, within the forecast period.

Lack of Targeted Therapies Being Addressed by Current Developmental Pipeline

There is currently a lack of targeted therapies indicated for the treatment of OC, certainly in comparison with other indications within oncology. Avastin is the only approved targeted therapy and was approved in the EU in 2011 on the basis of improved PFS. The current treatment of OC is dominated by the use of off-patent chemotherapeutic agents: primarily carboplatin, paclitaxel, pegylated liposomal doxorubicin, topotecan and gemcitabine. The current development pipeline appears to be focusing on this lack of targeted therapies, with a wide range of novel targets specific to ovarian tumor cell growth and progression, including growth factors, serine/threonine protein kinases and tumor-associated antigens/genes.

Improvements in Clinical Trial Design Necessary

Recent insights have highlighted that OC is a highly heterogeneous disease with mutations in a range of signaling pathways involved in the initiation and propagation of the disease. Furthermore associated mutations vary among the different histological subtypes and stages of the disease, adding further levels of complexity to the treatment of OC (Wang et al., 2005; Lawrenson et al., 2011). Clinical trials of marketed and current late-stage pipeline drugs have rarely taken this heterogeneity into account, and results across all patient cohorts are usually aggregated, regardless of patients' disease histology and variations in genetic alterations. The poor results obtained, particularly with pipeline drugs, demonstrate that this ''universal approach'' is not efficient, and more efforts need to be made to explore the effects of drugs in different disease subtypes. However, it is recognized that further molecular studies are necessary to fully understand the etiology of each disease histotype and make these analyses by subtype fully applicable (Karst and Drapkin, 2010). There is evidence that the genetic and epigenetic characteristics of patients are beginning to be taken into account. Post-hoc analyses of the late-stage pipeline drug olaparib demonstrated that this drug had improved efficacy in patients with Breast Cancer (BRCA) mutation.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Pathophysiology
    • 2.1.1. Ovarian Cancer - A Group of Distinct Diseases
    • 2.1.2. Ovarian Cancer is Highly Heterogenic, with Multiple Mutations and Affected Signaling Pathways
  • 2.2. Symptoms and Diagnosis
  • 2.3. Risk Factors
    • 2.3.1. Age
    • 2.3.2. Inherited Genetic Mutations
    • 2.3.3. Greater Number of Lifetime Ovulations
    • 2.3.4. Weight
    • 2.3.5. Previous Medical Conditions
  • 2.4. Treatment Algorithm
    • 2.4.1. Surgery
    • 2.4.2. First-Line Chemotherapy
    • 2.4.3. Maintenance Therapy
  • 2.5. Recurrent Disease

3. Marketed Products

  • 3.1. Carboplatin
  • 3.2. Paclitaxel
  • 3.3. Gemcitabine
  • 3.4. Topotecan
  • 3.5. Pegylated Liposomal Doxorubicin
  • 3.6. Yondelis
  • 3.7. Avastin

4. Product Pipeline

  • 4.1. Overview of Pipeline by Phase and Route of Administration
  • 4.2. Overview of Pipeline by Molecule Type, Mechanism of Action and Molecular Target
    • 4.2.1. Molecular Targets in the Developmental Pipeline
  • 4.3. Clinical Trials
    • 4.3.1. Clinical Trial Duration
    • 4.3.2. Clinical Trial Size
    • 4.3.3. Failure Rate
    • 4.3.4. Discussion

5. Late-Stage Drugs in Developmental Pipeline

  • 5.1. Profiles
    • 5.1.1. Niraparib
    • 5.1.2. Olaparib
    • 5.1.3. Abagovomab
    • 5.1.4. Vargatef
    • 5.1.5. Trebananib
    • 5.1.6. Farletuzumab
    • 5.1.7. Vynfinit
    • 5.1.8. Telcyta
    • 5.1.9. Karenitecin
  • 5.2. Discussion

6. Market Forecast

  • 6.1. Global Market
    • 6.1.1. Overview
    • 6.1.2. Treatment Patterns and Revenues in Top Eight Markets
  • 6.2. North America
    • 6.2.1. Treatment Usage Patterns
    • 6.2.2. Annual Cost of Therapy
    • 6.2.3. Market Revenues
  • 6.3. Top Five European Markets
    • 6.3.1. Treatment Usage Patterns
    • 6.3.2. Annual Cost of Therapy
    • 6.3.3. Market Forecasts
  • 6.4. Japan
    • 6.4.1. Treatment Usage Patterns
    • 6.4.2. Annual Cost of Therapy
    • 6.4.3. Market Forecast

7. Drivers and Barriers

  • 7.1. Drivers
    • 7.1.1. High Number of Candidates in Drug Development
    • 7.1.2. High Unmet Clinical Need
    • 7.1.3. Incentives for Orphan Drug Development
    • 7.1.4. Potential Changes to Clinical Trial Design
  • 7.2. Barriers
    • 7.2.1. Decreasing Incidence Rates
    • 7.2.2. Lack of Cell Lines
    • 7.2.3. High Heterogeneity of the Disease
    • 7.2.4. High Cost of Novel Drugs

8. Deals

  • 8.1. Licensing Deals
    • 8.1.1. Clovis Oncology Enters into Licensing Agreement with Pfizer for PF-01367338
    • 8.1.2. PharmaMar Enters into Licensing Agreement with Janssen for Yondelis
    • 8.1.3. Hana Enters into Licensing Agreement with Tekmira
    • 8.1.4. AstraZeneca Enters into Licensing Agreement with Merck for MK-1775
    • 8.1.5. Tesaro Enters into Licensing Agreement with Merck Sharp & Dohme for Cancer Drug
    • 8.1.6. Oasmia Enters into Licensing Agreement with Medison for Paclical
    • 8.1.7. Orion Enters into Agreement with Oasmia
    • 8.1.8. Ohio University Enters into Licensing Agreement with Phosplatin
    • 8.1.9. Genta Enters into Licensing Agreement with Daiichi Sankyo
    • 8.1.10. Celldex Enters into Licensing Agreement with the Ludwig Institute for Cancer Research
    • 8.1.11. NanoCarrier Enters into Licensing Agreement with Kowa for NC-6300
  • 8.2. Co-Development Deals
    • 8.2.1. Merck Enters into Co-Development Agreement with Endocyte for Cancer Drug
    • 8.2.2. Pfizer Enters into Research Agreement with BC Cancer Agency and Vancouver Prostate Centre
    • 8.2.3. Almac Discovery Enters into an Agreement with Queen's University Belfast for Drug Discovery

9. Appendix

  • 9.1. All Pipeline Drugs by Phase
    • 9.1.1. Discovery
    • 9.1.2. Preclinical
    • 9.1.3. IND/CTA-Filed
    • 9.1.4. Phase I
    • 9.1.5. Phase II
    • 9.1.6. Phase III
    • 9.1.7. Pre-Registration
  • 9.2. Market Forecasts to 2020
    • 9.2.1. Global
    • 9.2.2. The US
    • 9.2.3. Canada
    • 9.2.4. UK
    • 9.2.5. France
    • 9.2.6. Germany
    • 9.2.7. Italy
    • 9.2.8. Spain
    • 9.2.9. Japan
  • 9.3. Abbreviations
  • 9.4. Bibliography
  • 9.5. Methodology
  • 9.6. Secondary Research
  • 9.7. Contact Us
  • 9.8. Disclaimer

List of Tables

  • Table 1: Ovarian Cancer Therapeutics, Histological Subtypes and Associated Genetic Mutations
  • Table 2: Ovarian Cancer Therapeutics, Affected Signaling Pathways in Ovarian Cancer, Associated Mutations and Effects on Cancer Development
  • Table 3: Ovarian Cancer Therapeutics, Ovarian Cancer Disease Staging
  • Table 4: Ovarian Cancer Therapeutics, Eastern Cooperative Oncology Group Performance Status Scores and Description
  • Table 5: Ovarian Cancer Therapeutics, Common Endpoints in Ovarian Cancer and Details of Criteria
  • Table 6: Ovarian Cancer Therapeutics, Rates of Sensory and Motor Neuropathy with Pegylated Liposomal Doxorubicin and Paclitaxel in Combination with Carboplatin (%), 2010
  • Table 7: Ovarian Cancer Therapeutics, Yondelis Phase III Clinical Trial, Stratification of patients by Platinum-Free Interval (%), 2010
  • Table 8: Ovarian Cancer Therapeutics, Poly ADP Ribose Polymerase Inhibitors Under Development, 2013
  • Table 9: Ovarian Cancer Therapeutics, Epidermal Growth Factor Receptor Inhibitors Under Development, 2013
  • Table 10: Ovarian Cancer Therapeutics, Mucin Inhibitors Under Development, 2013
  • Table 11: Ovarian Cancer Therapeutics, Aurora Kinase Inhibitors Under Development, 2013
  • Table 12: Ovarian Cancer Therapeutics, Average Clinical Trial Duration across Each Phase for Ovarian Cancer, across Oncology and across Entire Industry (months), 2013
  • Table 13: Ovarian Cancer Therapeutics, Global, Patient Demographics of a Phase III Clinical Trial of Trebananib (%), 2011
  • Table 14: Ovarian Cancer Therapeutics, Efficacy Results of Phase III Clinical Trial, Telcyta, 2010
  • Table 15: Ovarian Cancer Therapeutics, Results of Phase III Clinical Trial, Telcyta, 2007
  • Table 16: Ovarian Cancer Therapeutics, Top Five European Union Markets, Incidence Rates (per 100,000), 2008-2012
  • Table 17: Ovarian Cancer Therapeutics, Global, Developmental Pipeline, Discovery Phase, 2013
  • Table 18: Ovarian Cancer Therapeutics, Global, Developmental Pipeline, Preclinical Phase, 2013
  • Table 19: Ovarian Cancer Therapeutics, Global, Developmental Pipeline, IND/CTA Filed, 2013
  • Table 20: Ovarian Cancer Therapeutics, Global, Developmental Pipeline, Phase I, 2013
  • Table 21: Ovarian Cancer Therapeutics, Global, Developmental Pipeline, Phase II, 2013
  • Table 22: Ovarian Cancer Therapeutics, Global, Developmental Pipeline, Phase III, 2013
  • Table 23: Ovarian Cancer Therapeutics, Global, Developmental Pipeline, Pre-Registration, 2013
  • Table 24: Ovarian Cancer Therapeutics, Global, Market Forecast, 2013-2020
  • Table 25: Ovarian Cancer Therapeutics, The US, Market Forecast, 2013-2020
  • Table 26: Ovarian Cancer Therapeutics, Canada, Market Forecast, 2013-2020
  • Table 27: Ovarian Cancer Therapeutics, UK, Market Forecast, 2013-2020
  • Table 28: Ovarian Cancer Therapeutics, France, Market Forecast, 2013-2020
  • Table 29: Ovarian Cancer Therapeutics, Germany, Market Forecast, 2013-2020
  • Table 30: Ovarian Cancer Therapeutics, Italy, Market Forecast, 2013-2020
  • Table 31: Ovarian Cancer Therapeutics, Spain, Market Forecast, 2013-2020
  • Table 32: Ovarian Cancer Therapeutics, Japan, Market Forecast, 2013-2020
  • Table 33: Abbreviations

List of Figures

  • Figure 1: Ovarian Cancer Therapeutics, Efficacy Results for Key Parameters - Marketed Products, First-Line and Maintenance Therapies
  • Figure 2: Ovarian Cancer Therapeutics, Safety Results for Key Parameters - Marketed Products, First-Line and Maintenance Therapies
  • Figure 3: Ovarian Cancer Therapeutics, Efficacy Results for Key Parameters - Marketed Products, Recurrent Disease: All Patients
  • Figure 4: Ovarian Cancer Therapeutics, Safety Results for Key Parameters - Marketed Products, Recurrent Disease: All Patients
  • Figure 5: Ovarian Cancer Therapeutics, Efficacy Results for Key Parameters - Marketed Products, Recurrent Disease: Platinum-Sensitive
  • Figure 6: Ovarian Cancer Therapeutics, Safety Results for Key Parameters - Marketed Products, Recurrent Disease: Platinum-Sensitive
  • Figure 7: Ovarian Cancer Therapeutics, Efficacy Results for Key Parameters - Marketed Products, Recurrent Disease: Platinum-Resistant
  • Figure 8: Ovarian Cancer Therapeutics, Safety Results for Key Parameters - Marketed Products, Recurrent Disease: Platinum-Resistant
  • Figure 9: Ovarian Cancer Therapeutics, Global, Pipeline Distribution by Stage, Program Type and Route of Administration, 2013
  • Figure 10: Ovarian Cancer Therapeutics: Global, Pipeline by Molecule Type and Mechanism of Action, 2013
  • Figure 11: Ovarian Cancer Therapeutics, Global, Molecular Targets of the Developmental Pipeline, 2013
  • Figure 12: Ovarian Cancer Therapeutics, Global, Clinical Trial Duration (months), 2006-2013
  • Figure 13: Ovarian Cancer Therapeutics, Global, Clinical Trial Size (participants), 2006-2013
  • Figure 14: Ovarian Cancer Therapeutics, Global, Clinical Trial Failure Rate and Reasons for Failure (%), 2006-2013
  • Figure 15: Ovarian Cancer Therapeutics, Global, Overview of Clinical Trial Failure Rate, Duration and Size by Phase and Molecule Type, 2006-2013
  • Figure 16: Ovarian Cancer Therapeutics, Global, Forecast Revenues of Olaparib ($m), 2014-2020
  • Figure 17: Ovarian Cancer Therapeutics, Global, Forecast Revenues of Trebananib ($m), 2016-2020
  • Figure 18: Ovarian Cancer Therapeutics, Global, Forecast Revenues of Vynfinit ($m), 2016-2020
  • Figure 19: Ovarian Cancer Therapeutics, Efficacy Results for Key Parameters - Pipeline (blue) and Marketed Products Comparison. Recurrent Disease: All Patients
  • Figure 20: Ovarian Cancer Therapeutics, Safety Results for Key Parameters - Pipeline (blue) and Marketed Products Comparison. Recurrent Disease: All Patients
  • Figure 21: Ovarian Cancer Therapeutics, Efficacy Results for Key Parameters - Pipeline (blue) and Marketed Products Comparison. Recurrent Disease: Platinum-Sensitive
  • Figure 22: Ovarian Cancer Therapeutics, Safety Results for Key Parameters - Pipeline (blue) and Marketed Products Comparison. Recurrent Disease: Platinum-Sensitive
  • Figure 23: Ovarian Cancer Therapeutics, Efficacy Results for Key Parameters - Pipeline (blue) and Marketed Products Comparison. Recurrent Disease: Platinum-Resistant
  • Figure 24: Ovarian Cancer Therapeutics, Efficacy Results for Key Parameters - Pipeline (blue) and Marketed Products Comparison. Recurrent Disease: Platinum-Resistant
  • Figure 25: Ovarian Cancer Therapeutics, Global, Treatment Usage Patterns and Market Revenues ('000; $m), 2013-2020
  • Figure 26: Ovarian Cancer Therapeutics, US and Canada, Treatment Usage Patterns ('000), 2013-2020
  • Figure 27: Ovarian Cancer Therapeutics, US and Canada, Annual Cost of Therapy ($), 2013-2020
  • Figure 28: Ovarian Cancer Therapeutics, US and Canada, Market Revenues ($m), 2013-2020
  • Figure 29: Ovarian Cancer Therapeutics, Top Five European Union Markets, Treatment Usage Patterns ('000), 2013-2020
  • Figure 30: Ovarian Cancer Therapeutics, Top Five European Union Markets, Annual Cost of Therapy ($), 2013-2020
  • Figure 31: Ovarian Cancer Therapeutics, Top Five European Union Markets, Market Revenues ($m), 2013-2020
  • Figure 32: Ovarian Cancer Therapeutics, Japan, Treatment Usage Patterns ('000), 2013-2020
  • Figure 33: Ovarian Cancer Therapeutics, Japan, Annual Cost of Therapy ($), 2013-2020
  • Figure 34: Ovarian Cancer Therapeutics: Japan, Market Revenues ($m), 2013-2020
  • Figure 35: Ovarian Cancer Therapeutics, Global, Licensing Deals by Location, Year and Value, 2006-2013
  • Figure 36: Ovarian Cancer Therapeutics, Global, Licensing Deals by Phase, Molecule Type and Mechanism of Action, 2006-2013
  • Figure 37: Ovarian Cancer Therapeutics, Global, Co-Development Deals by Location, Year and Value, 2006-2013
Back to Top